Zacks Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.6M | Sell |
55,082
-1,544
| -3% | -$720K | 0.2% | 113 |
|
|
2025
Q4 | $25.7M | Sell |
56,626
-1,400
| -2% | -$603K | 0.2% | 119 |
|
|
2025
Q3 | $22.7M | Buy |
58,026
+3,710
| +7% | +$1.55M | 0.18% | 127 |
|
|
2025
Q2 | $24.2M | Sell |
54,316
-31,734
| -37% | -$14.6M | 0.21% | 122 |
|
|
2025
Q1 | $41.7M | Buy |
86,050
+33,397
| +63% | +$15.6M | 0.39% | 73 |
|
|
2024
Q4 | $21.2M | Sell |
52,653
-9,831
| -16% | -$4.56M | 0.2% | 123 |
|
|
2024
Q3 | $29.1M | Buy |
62,484
+2,719
| +5% | +$1.31M | 0.25% | 104 |
|
|
2024
Q2 | $28M | Buy |
59,765
+5,432
| +10% | +$2.36M | 0.32% | 77 |
|
|
2024
Q1 | $22.7M | Buy |
54,333
+53,662
| +7,997% | +$22.7M | 0.24% | 104 |
|
|
2023
Q4 | $273K | Buy |
+671
| New | +$248K | ﹤0.01% | 543 |
|
|
2023
Q3 | – | Sell |
-1,224
| Closed | -$431K | – | 714 |
|
|
2023
Q2 | $431K | Sell |
1,224
-430
| -26% | -$145K | 0.01% | 480 |
|
|
2023
Q1 | $521K | Sell |
1,654
-13,031
| -89% | -$3.91M | 0.01% | 447 |
|
|
2022
Q4 | $4.24M | Buy |
14,685
+1,043
| +8% | +$318K | 0.06% | 205 |
|
|
2022
Q3 | $3.95M | Sell |
13,642
-15,649
| -53% | -$4.5M | 0.06% | 194 |
|
|
2022
Q2 | $8.25M | Buy |
29,291
+376
| +1% | +$101K | 0.13% | 136 |
|
|
2022
Q1 | $7.54M | Buy |
+28,915
| New | +$6.86M | 0.1% | 155 |
|
|
2021
Q4 | – | Sell |
-1,253
| Closed | -$227K | – | 683 |
|
|
2021
Q3 | $227K | Sell |
1,253
-30,207
| -96% | -$5.9M | ﹤0.01% | 565 |
|
|
2021
Q2 | $6.34M | Sell |
31,460
-8,190
| -21% | -$1.71M | 0.1% | 160 |
|
|
2021
Q1 | $8.52M | Buy |
39,650
+10,903
| +38% | +$2.39M | 0.15% | 135 |
|
|
2020
Q4 | $6.79M | Sell |
28,747
-8,417
| -23% | -$1.93M | 0.13% | 140 |
|
|
2020
Q3 | $10.1M | Sell |
37,164
-7,711
| -17% | -$2.13M | 0.2% | 110 |
|
|
2020
Q2 | $13M | Buy |
44,875
+2,538
| +6% | +$688K | 0.29% | 84 |
|
|
2020
Q1 | $10.1M | Buy |
42,337
+10,610
| +33% | +$2.43M | 0.25% | 99 |
|
|
2019
Q4 | $6.95M | Buy |
31,727
+1,637
| +5% | +$331K | 0.13% | 131 |
|
|
2019
Q3 | $5.1M | Buy |
+30,090
| New | +$5.32M | 0.1% | 148 |
|
|
2017
Q4 | – | Sell |
-7,937
| Closed | -$1.21M | – | 653 |
|
|
2017
Q3 | $1.21M | Buy |
+7,937
| New | +$1.19M | 0.03% | 334 |
|
|
2016
Q1 | – | Sell |
-4,464
| Closed | -$562K | – | 690 |
|
|
2015
Q4 | $562K | Buy |
4,464
+95
| +2% | +$11.5K | 0.02% | 397 |
|
|
2015
Q3 | $455K | Sell |
4,369
-9
| -0.2% | -$1.16K | 0.02% | 443 |
|
|
2015
Q2 | $541K | Buy |
+4,378
| New | +$552K | 0.02% | 427 |
|
|
2014
Q3 | – | Sell |
-12,327
| Closed | -$1.17M | – | 756 |
|
|
2014
Q2 | $1.17M | Buy |
+12,327
| New | +$864K | 0.04% | 233 |
|
Other funds holding VRTX
VCM
VPM
Zacks Investment Management's VRTX Position: Q1 2026 in Review
Zacks Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q1 2026, selling an estimated $720K and leaving 55,082 shares worth $24.6M. The position accounts for 0.2% of the portfolio, ranked #113.
Zacks Investment Management first reported a position in VRTX in Q2 2014 and has held it in 30 quarters since. The position peaked at $41.7M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Zacks Investment Management held 55,082 shares of Vertex Pharmaceuticals worth $24.6M as of Q1 2026.
- Zacks Investment Management sold 1,544 Vertex Pharmaceuticals shares in Q1 2026, an estimated $720K.
- Vertex Pharmaceuticals made up 0.2% of Zacks Investment Management's portfolio in Q1 2026, its #113 holding.
- Zacks Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 30 quarters since.
- Zacks Investment Management's Vertex Pharmaceuticals position peaked at $41.7M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.